Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-07-17
2011-10-25
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
Reexamination Certificate
active
08043616
ABSTRACT:
Mammalian sRAGE mimetibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to reduce or inhibit the binding of RAGE and its ligands and to treat RAGE-related diseases are also disclosed.
REFERENCES:
patent: 5202424 (1993-04-01), Vlassara et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5852174 (1998-12-01), Vlassara et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 6004958 (1999-12-01), Brown et al.
patent: 6465422 (2002-10-01), Schmidt et al.
patent: 6555651 (2003-04-01), Stern et al.
patent: 6563015 (2003-05-01), Stern et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 6753150 (2004-06-01), Schmidt et al.
patent: 6790443 (2004-09-01), Stern et al.
patent: 6825164 (2004-11-01), Stern et al.
patent: 6908741 (2005-06-01), Shahbaz
patent: 7166707 (2007-01-01), Feige
patent: 7217799 (2007-05-01), Raitano et al.
patent: 7241733 (2007-07-01), Heavner et al.
patent: 7393662 (2008-07-01), Heavner et al.
patent: 2001/0053357 (2001-12-01), Stern et al.
patent: 2003/0082749 (2003-05-01), Sun et al.
patent: 2003/0170626 (2003-09-01), Raitano et al.
patent: 2004/0142391 (2004-07-01), Schmidt et al.
patent: 2004/0210042 (2004-10-01), Tsuchida
patent: 2005/0026811 (2005-02-01), Mjalli et al.
patent: 2005/0033017 (2005-02-01), Yamamoto et al.
patent: 2005/0129682 (2005-06-01), Schmidt et al.
patent: WO 93/04086 (1993-03-01), None
patent: WO 97/39121 (1997-10-01), None
patent: WO 97/39125 (1997-10-01), None
patent: WO 98/22138 (1998-05-01), None
patent: WO 99/07402 (1999-02-01), None
patent: WO 99/18987 (1999-04-01), None
patent: WO 99/54485 (1999-10-01), None
patent: WO 01/92210 (2001-12-01), None
patent: WO 01/92892 (2001-12-01), None
patent: WO 02/070667 (2002-09-01), None
patent: WO 03/084477 (2003-10-01), None
patent: WO 2004/002417 (2004-01-01), None
patent: WO 2004/002424 (2004-01-01), None
patent: WO2004/016229 (2004-02-01), None
patent: WO 2005/032460 (2005-04-01), None
patent: WO 2006/017643 (2006-02-01), None
Xu et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. Feb. 25, 2000;200(1):16-26.
R&D Systems, Inc. “Recombinant Human Rage/Fc Chimera,” Catalog No. 1145-RG, Internet Citation May 3, 2004.
Rouhiainen, et al., “Regulation of monocyte migration by amphoterin (HMGB1),” Blood, 104(4): 1174-1182 (2004).
Huttunen, et al., “Receptor for Advanced Glycation End Products-binding COOH-terminal Motif of Amphoterin Inhibits Invasive Migration and Metastasis,” Cancer Research, 62: 4805-4811 (2002).
Supplemental EP Search Report dated Dec. 18, 2008.
Aalberse, et al., “IgG4 breaking the rules,” Immunology, 105: 9-19 (2002).
Deane, et al., “RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain,” Nature Medicine, 9: 907-913 (2003).
Hofmann, et al., “RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100 Calgranulin Polypeptides,” Cell, vol. 97: 889-901 (1999).
Hori, et al., “The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin,” The Journal of Biological Chemistry, 270(43): 25752-25761 (1995).
Kislinger, et al., “Nε-9Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products that Activate Cell Signaling Pathways and Modulate Gene Expression,” The Journal of Biological Chemistry, 274(44): 31740-31749 (1999).
Park, et al., “Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts,” Nature Medicine: 4(9): 1025-1031 (1998).
Scaffidi, et al., “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation,” Nature, 418: 191-195 (2002).
Schmidt, et al., “Isolation and Characterization of Two Binding Proteins for Advanced Glycosylation End Products from Bovine Lung Which are Present on the Endothelial Cell Surface,” The Journal of Biological Chemistry, 267(21): 14987-14997 (1992).
Schmidt, et al., “The dark site of glucose,” Nature Medicine, 1(10): 1002-1004 (1995).
Taguchi, et al., “Blocade of RAGE-amphoterin signaling suppresses tumour growth and metastases,” Nature, 405: 354-260 (2000).
Wang, et al., “HMG-1 as a Late Mediator of Endotoxin Lathality in Mice,” Science, 285: 248-251 (1999).
Yan, et al., “RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease,” Nature, 382: 685-691 (1996).
Renard, et al., “Recombinant Advanced Glycation End Product Receptor Pharmacokinetics in Normal and Diabetic rates,” Molecular Pharmacology, 52: 54-62 (1997).
Lotze, et al., “Dealing with death: HMGB1 as a novel target for cancer therapy,” Current Opinion in Investigational Drugs, 4: 1405-1409 (2003).
Zhang, et al., “Targeting of functional antibody-CD59 fusion proteins to a cell surface,” The Journal of Clinical Investigation, 103(1): 55-61 (1999).
Shin, et al., “Transferrin-antibody fusion proteins are effective in brain targeting,” Proceedings of the National Academy of Sciences USA, 92: 2820-2824 (1995).
Lilley, et al, “Recombinant single-chain antibody peptide conjugates expressed inEscherichia colifor the rapid diagnosis of HIV,” Journal of Immunological Methods, 171: 211-226 (1994).
Koyama, et al., “RAGE and soluble RAGE: Potential therapeutic targets for cardiovascular diseases,” Molecular Medicine, 13 (11-12): 625-635 (2007).
Yan, et al., “Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors,” Science, 290: 523-527 (2000).
W.E. Paul, Fundamental Immunology, 3rded., 292-295 (1993).
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National
PCT International Search Report dated Jul. 12, 2006.
Anderson Glenn Mark
Jordan Robert
Picha Kristen
Baumeister Kirk
Centocor, Inc.
Emch Gregory S
Kolker Daniel E
LandOfFree
sRAGE mimetibody, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with sRAGE mimetibody, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and sRAGE mimetibody, compositions, methods and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4275119